Where's AbbVie's next "Shumeile"? When will Takeda continue to "sell"? How do Big Mac drug companies retain their "status"?

Patent expiration, revenue pressure, the sharp increase in the cost of research and development of new drugs and other issues are forcing pharmaceutical companies to enrich their product pipeline through mergers and acquisitions.
and AbbVie reach the growth they are looking for after completing more than $60 billion in sky-high deals? 01 Back to the blood and focus this time, Takeda is no longer crazy "selling and selling".
January 13, Takeda Pharmaceuticals and biotech company KSQ Therapeutics reached an extensive strategic partnership to use its proprietary CRISPRomics® discovery platform to systematically screen the entire genome to identify the best genetic targets for tumors and autoimmune diseases to research, develop and commercialize new immune-based cancer treatments.
As Christopher Weber, President and CEO of Takeda Pharmaceuticals, said at the 38th J.P. Morgan Healthcare Conference, "The current Takeda focuses on four areas: oncology, rare diseases, neuroscience, and digestion, and transforms it into a head biopharmaceutical company driven by R and D."
" huge investment in the acquisition of Shire, so that Takeda Pharmaceuticals on a long road back to the blood.
, Asia's largest biopharmaceutical company, became the world's largest rare-disease pharmaceutical company in 2019 when it completed the acquisition of Shire for $62.2 billion.
, the heavy-money acquisition of Shire has also put a huge financial pressure on Takeda Pharmaceuticals, which is in debt of about $31 billion.
to sell $10bn of non-core assets during the period in an effort to meet its target of reducing net debt by 2024.
since January 2019, Takeda has announced 11 divestitures of non-core assets worldwide, totalling about $11.6 billion.
sold Dry Eye Products Xiidra to Novaral for $5.3 billion; TachoSil, a surgical patch designed to control bleeding, to Johnson and Johnson subsidiary Ethicon for $400 million; and Tooka Consumer Health for about $2.3 billion to Oscar A-Co KK, controlled by US private equity giant Blackstone Group; and nearly $2 billion to four buyers of non-core businesses in growth and emerging markets; $670 million divestiture of some of Europe's over-the-counter and non-core businesses to Origin; divestment of non-core businesses in Europe and Canada to U.S. company Cheplapharm for about $562 million; divestiture of TachoSil fibrin closed patches to Corza Health for about 500 million euros; divestiture of 18 pharmaceutical and over-the-counter (OTC) products sold in the Asia-Pacific region to Celltrion, South Korea, for $278 million; As recently as December 21 last year, Takeda "extended" its spin-off tentacles to Chinese mainland, announcing a $322 million divestiture of part of its prescription drug business at Chinese mainland to Heisman Biopharmaceuticals, which includes Takeda's portfolio in the cardiovascular and metabolic sectors sold by Chinese mainland.
"Takeda plans to continue to pay its debts through the proceeds of the divestiture of the business between fiscal 2021 and fiscal 2023," he said.
Reuters", Said Christopher Weber, president and chief executive of Takeda Pharmaceuticals, said that after the transformational acquisition of Shire, Takeda had proposed a growth strategy and that divesting the products was an important step forward.
as a value-based, research-and-development-oriented global biopharmaceutical company, Takeda focuses more on gastroenterology (GI), rare diseases, plasma-derived therapies, oncology and neuroscience.
" Takeda plans to use the proceeds from divestitures of these products to reduce debt while simplifying its portfolio and accelerating deleveraging to achieve its target of 2.0 times net/adjusted EBITDA in the inflow.
38th J.P. Morgan Healthcare Conference, Weber showed global investors the latest developments in Takeda Pharmaceuticals' continued transformation and growth.
" Takeda Pharmaceuticals expects 12 new products to be launched in fiscal year 2024, more than 15 new products to be launched in China in the next five years, 50 percent of the pipeline will be orphan drugs, 70 percent of the pipeline will rely on cell therapy, gene therapy, microorganisms, peptides and oligonucleotides and other technologies, and more than 4,500 researchers worldwide will be engaged in research and development of new drugs.
", Takeda's Wave 1 program (five-year plan) includes five programs that have been recognized for breakthrough treatments and three that have been approved by the FDA for fast track.
forecast that there will be 12 key milestones, including five key data releases, by FY2022.
In addition to the Wave 1 research and development pipeline, Takeda's research engine, which includes in-house research and development capabilities and more than 200 active partnerships, is rapidly and steadily advancing the Wave 2 (Ten-Year Plan) research and development pipeline, which will continue to grow in fiscal 2025 and beyond.
these Wave 2 early clinical and preclinical programs will provide transformational or therapeutic potential for highly unsolveed target populations in the core therapeutic areas.
based on powerful human-proven targets, they represent multiple models and take advantage of new platform capabilities in the fields of cell therapy, gene therapy, and data science.
stressed that Takeda has solid growth momentum and has the potential to accelerate potential growth in the medium term.
is on track to achieve a $2.3 billion annual operating rate of the cost synergies target by the end of fiscal 2021, further supporting margin performance to meet the medium-term core operating margin target for the mid-30s.
, the continued divestiture of non-core businesses and focus on the main areas will be the main theme of Takeda's next decade.
02 The Aura of the Drug King fades, where does AbbVie go from when the Drug King Shumeile Halo is no longer, and what kind of attitude can we expect AbbVie to grow? This may be a question in the minds of investors around the world.
since the listing of Shumeile, has been approved in the United States and the European Union and other places for the treatment of rheumatoid arthritis, strong spina bifida, psoriasis and Crohn's disease and other 14 kinds of adaptive disorders.
2017-2018, the company's sales reached $18.4 billion and $19.9 billion, respectively, ranking first in the world in prescription drug sales for many years.
2019, the company is once again unquestionably the world's best-selling drug, with sales of $19.73 billion dropping nearly $10 billion.
but almost certainly it will be the pinnacle of Theo Mele.
in the European market, Symele is being challenged by a range of biosimilars such as Amjin and Novarma, while AbbVie is continuing its efforts to protect its market share in Europe and maintain its position as the world's best-selling drug.
same time, AbbVie has delayed sales of biosynthic drugs in the U.S. until 2023.
none of this will stop the arrival of the Shumeile patent cliff.
impact of generics could bring sales to $6.83 billion by 2026, according to Evaluate Pharma, the company's research agency.
at home, Shumeile's situation is equally bleak.
In 2010, Shumeile was approved for listing in China, and has been approved for rheumatoid arthritis, strong straightening spina bifidos, plaque-like psoriasis, multi-joint type of young idlygenic arthritis adaptation, adult Crohn's disease and adult non-infectious intermediate, post, whole grape membraneitis 6 adaptations.
, as a biosynthic drug of Shumeile, the number of domestic research Adamu single anti-enterprise more than 20, the impact of market competition on the original research drug companies has emerged.
November 2019, Biopharmaceutical Co., Ltd. announced that the company's self-developed Greeley was officially approved by the State Drug Administration, becoming the first Adamu monobial-like drug approved in China.
, Haizheng Pharmaceuticals, Xinda Bio, and Fuhong Hanxuan's Adamo single resistance were approved one after another.
in addition to approved manufacturers, including Zhengda Tianqing, Qilu and Junshi Biological and other pharmaceutical companies are developing Adamo single resistance.
market size of Adamo monobiotics is expected to grow to 4.7 billion yuan by 2023 and 11.5 billion yuan by 2030, according to the Frost Sullivan report.
, in contrast to the original drug company, sales outside the U.S. were $4.305 billion in 2019, down 31.1 percent from a year earlier.
With Xinda Bio's announcement in December that its Adamo monoantigen injection (Su Lixin) had been approved by the State Drug Administration for two new adaptations, SuLixin had approved six adaptations.
analysis generally believes that, with the increase of approved adaptive diseases, the domestic market competition for Adamo mono-biosynthic drugs will be more intense, the first-mover position of Shumeile is no longer obvious.
continued decline in sales of the "cash cow" Shumeile, which makes it urgent for AbbVie to find other innovative drugs to complement its product line, a condition that AerIen, which is struggling with, is meeting.
AbbVie previously announced that the deal achieves unique and complementary strategic objectives for AbbVie and AerGem, combining AerBoa's diversified market portfolio with AbbVie's growth platform, as well as strong research and development and commercial and international expansion capabilities, to create a The world's leading biopharmaceutical company, Al-Jian's product portfolio will also be strengthened by AbbVie's commercial strength and existing international business network, which will reduce the company's reliance on Shumeile and keep the company's focus on high-innovation science for the next decade.
's combined business will cover the immunology, hematology, medical beauty, neurology, women's health, ophthalmology and virology sectors, covering more than 175 countries, with industry-leading research and development pipelines and strong cash flow.
, AbbVie, which completed the $63 billion acquisition, has become the world's largest prescription drug company.
, which was completed by the company, owns Shumeile, Skyrizi and Rinvoq in immunology, as well as Eyre and Venclexta in the field of blood tumours.
In neuroscience, Aergen's Prudentifico, Vraylar and Ubrelvy bring new growth opportunities to AbbVie, while in aesthetics, AerGen brings global business to brands such as Prudentifico and Joe Yaden.
's most important concern for the investment community is the loss of Symeyer due to the patent cliff, and AbbVie CEO Richard Gonzalez detailed at the 38th J.P. Morgan Healthcare Conference how AbbVie plans to overcome the huge losses suffered by the company's loss of exclusive rights in 2023.
With multiple biosimilars due to be launched in the U.S. in 2023, "Skyrizi and Rinvoq are two new immunological products that will generate $15 billion in sales by 2025, which could largely compensate for the decline in sales and even replace Symele's position."
"Gonzalez is blunt.
, AbbVie's hematology and neurology drugs are expected to grow in sales over the next few years.
he expects AbbVie to return to revenue growth the year after the storm hit, and that growth will accelerate in 2025 and beyond.